Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation and Depletion (2016 - 2020)

Agios Pharmaceuticals (AGIO) has disclosed Depreciation and Depletion for 8 consecutive years, with $2.4 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Depreciation and Depletion rose 19.39% year-over-year to $2.4 million, compared with a TTM value of $8.9 million through Jun 2020, up 13.96%, and an annual FY2025 reading of $5.2 million, down 8.77% over the prior year.
  • Depreciation and Depletion was $2.4 million for Q2 2020 at Agios Pharmaceuticals, down from $2.5 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $2.5 million in Q1 2020 and bottomed at $1.2 million in Q1 2016.
  • Average Depreciation and Depletion over 5 years is $1.8 million, with a median of $1.7 million recorded in 2018.
  • The sharpest move saw Depreciation and Depletion soared 236.76% in 2016, then decreased 5.81% in 2017.
  • Year by year, Depreciation and Depletion stood at $1.7 million in 2016, then dropped by 5.81% to $1.6 million in 2017, then rose by 19.54% to $1.9 million in 2018, then fell by 3.25% to $1.9 million in 2019, then increased by 29.64% to $2.4 million in 2020.
  • Business Quant data shows Depreciation and Depletion for AGIO at $2.4 million in Q2 2020, $2.5 million in Q1 2020, and $1.9 million in Q4 2019.